Javara Inc. and Wake Forest Baptist Health Partner to Amplify Trial Access
Javara Inc. and Wake Forest Baptist Health have signed an Integrated Research Agreement which extends their existing partnership to provide clinical research services at the point of care with physicians and patients within Wake Forest Baptist Health’s community health care clinics and designated medical centers. This agreement forms a relationship between the Wake Forest Baptist Health system and Javara’s research team to provide clinical research as a care option extends to patients across the 24 counties that Wake Forest Baptist serves.
Expanded clinical trial operations between Javara and Wake Forest Baptist are expected to begin in May 2021.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
